As mentioned above, most of the previous preclinical studies testing second-generation TSPO tracers have primarily used either acute excitotoxic lesion models or models of stroke relevant to the strong levels of NI observed in stroke or brain trauma. The gene discussed is TSPO; the disease is Stroke.